Cbd Life Science Stock Price, News & Analysis

CBD Life Sciences (OTC PINK:CBDL) announced the launch of a Mushroom-Infused Dubai Chocolate Bar through its subsidiary CBD Vault on October 21, 2025. The premium bar blends pistachio-filled Dubai-style chocolate with Cordyceps and Reishi extracts, positioning the company at the intersection of luxury confectionery and functional wellness.

The release cites the Dubai chocolate market > $1.5 billion with a 6.8% annual growth rate and a projected $35 billion global functional mushroom market by 2030 (CAGR 10.8%). CBDL says it will add the product to its Mushroom Madness line and pursue international and domestic distribution, expecting recurring revenue in Q4 2025 and through 2026.

CBD Life Sciences (OTC:CBDL) announced a major retail expansion after a large order from Smoking Scholars dispensary in the Bronx on October 14, 2025. CBDL's top-selling beverages — 16oz 50mg CBD Lemonade, 16oz 25mg CBD Raspberry Lemonade, 16oz 25mg CBD Lavender Lemonade, and CBD-infused water — will appear on Smoking Scholars' shelves, supporting the company’s East Coast retail push.

The company cites strong consumer demand, NECANN conference leads, and a growing regional pipeline across New Jersey and Pennsylvania, with management projecting recurring bulk orders and potential six-figure monthly sales as additional dispensaries onboard.

CBD Life Sciences (OTC:CBDL) has secured a strategic partnership with Smoking Scholars, a premier Bronx dispensary, marking a significant expansion into the New York cannabis market. The agreement includes an initial order of various CBD products including pain relief cream, massage oil, gummies, tea, and mushroom face cream.

The partnership emerged following CBDL's successful showcase at the NECANN New Jersey Conference and is expected to generate hundreds of thousands in revenue within 12 months. This move positions CBDL strategically in the New York market, where dispensary sales are projected to reach $4.4 billion by 2027. The company is actively pursuing additional partnerships across the Northeast region.

CBD Life Sciences (OTC:CBDL) has signed a Letter of Intent (LOI) with a licensed New Jersey dispensary, marking a strategic entry into the East Coast cannabis market. The partnership establishes a unique dual-channel distribution model where CBD Vault's products will be featured in the New Jersey dispensary while the dispensary's products will be sold in CBDL's retail locations.

The company expects this partnership to generate seven-figure annual revenues and serve as a springboard for expansion in the East Coast corridor. The New Jersey cannabis market alone is projected to exceed $2 billion annually by 2026, while the broader U.S. CBD and cannabis sector is forecasted to reach $33 billion by 2030.

CBD Life Sciences Inc. (OTC:CBDL) reports significant momentum following its participation at NECANN New Jersey 2025, one of the largest cannabis trade shows in the country. The company has entered into advanced negotiations with five major dispensaries across Pennsylvania & New Jersey, potentially accessing thousands of retail customers.

CBDL is also expanding its beverage portfolio, with CBD Seltzer and CBD Lemonade Drink planned for distribution in sports stadiums. The U.S. marijuana dispensary market is projected to reach $31.8 billion annually by 2025, with CBD-infused beverages showing a CAGR exceeding 20%. The company's dual strategy focuses on dispensary expansion and mass-market beverage distribution in sports venues.

CBD Life Sciences (OTC:CBDL) reports that President Trump's administration is actively considering rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act. This potential regulatory shift could transform the $30+ billion cannabis market by eliminating IRS Section 280E restrictions and opening doors for institutional investment.

The rescheduling would enable cannabis companies to deduct ordinary business expenses, improve net margins, and facilitate access to banking services. With nearly 70% of Americans supporting legalization, CBDL is positioning itself through retail expansion, including recent approval for sales on Walmart Marketplace, to capitalize on the anticipated industry growth following regulatory reform.

CBD Life Sciences (OTC:CBDL) announced its participation in the NECANN Cannabis Conference, scheduled for September 5-6, 2025, in Atlantic City, NJ. The company will showcase its flagship brand The CBD Vault at Booth 837.

NECANN New Jersey, ranked as the 3rd largest B2B cannabis convention in the US, is expected to attract over 5,000 attendees and feature more than 200 exhibitors. The event provides CBDL with opportunities to strengthen distribution networks, expand market reach, and connect with potential investors in the Mid-Atlantic region.

The global CBD market is projected to reach $69 billion by 2029, with a CAGR exceeding 31%. This exhibition aligns with CBDL's strategy to enhance brand visibility and capture market share in one of the nation's fastest-growing regions.

CBD Life Sciences Inc. (OTC:CBDL) has announced its expansion into Las Vegas, entering final negotiations for a premium retail location near the Las Vegas Strip. The company is also in advanced discussions with a Nevada-based boutique wellness retailer to carry CBDL's products.

The Las Vegas CBD market showed 27% year-over-year growth in 2024 and is projected to exceed $550 million by 2026. The strategic location will provide access to over 30 million annual visitors and leverage the city's 150,000+ hotel rooms for maximum brand exposure.

The expansion includes plans to offer CBDL's product line including CBD bath bombs, skincare items, and 8000mg pain relief creams through high-touchpoint boutique channels.

CBD Life Sciences (OTC:CBDL) is finalizing a lease agreement for its second retail location in Arizona's Chandler Fashion Center, marking a significant expansion of its physical presence. The strategic move positions CBDL in a high-traffic mall environment operated by a major management company overseeing 20+ retail properties nationwide.

The new store will showcase CBDL's premium product lines, including their 8000mg Nano CBD Pain Cream, Delta-8 Gummies, Mushroom Gummies, and CBD Coffee Creamers. The location will offer in-store sampling, education, and wellness consultations.

This expansion aligns with projections for the U.S. CBD market to reach $36 billion by 2032, growing at a 21.7% CAGR. The strategic location in a premier mall positions CBDL to capture significant foot traffic and potentially expand to other locations through the mall operator's nationwide network.